BUSINESS

Sarepta Drops DMD Drug Patent Claim against Nippon Shinyaku in Japan

January 31, 2025

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Nippon Shinyaku said on January 30 that its lawsuit with Sarepta Therapeutics in Japan over the Duchenne muscular dystrophy (DMD) treatment Viltepso (viltolarsen) has been terminated after the US biotech waived its patent infringement claim.The lawsuit had been filed by…

To read the full story

Nippon Shinyaku’s Viltepso Patents Invalid: US Jury Verdict
December 24, 2024
Nippon Shinyaku Sues Sarepta over DMD Therapy Patents in US
July 15, 2021

BUSINESS

Takeda Taps Halozyme’s Delivery Tech to Develop New Entyvio SC Formulation
January 13, 2026
Japan Heart Failure Drug Market Seen 1.5-Fold Growth by 2030: Fuji Keizai
January 13, 2026
Daito Secures China Approval for EquMet Generic
January 13, 2026
Japan Ethical Drug Sales Edge Up 0.4% in November: Crecon
January 13, 2026
Bayer/Santen to Launch Eylea Bio-AG on February 2
January 9, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Gist of FY2026 Drug Pricing Reform Outline

The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…

COMMENTARY

Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026

By Shinya Sato

As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…